Skip to main content
Top
Published in: International Journal of Hematology 1/2017

01-07-2017 | Case Report

First case report of hemophilia B Leyden in Japan

Authors: Atsuki Yamashita, Chiai Nagae, Mika Mori, Tomoko Ashikaga, Tetsuhito Kojima, Masashi Taki

Published in: International Journal of Hematology | Issue 1/2017

Login to get access

Abstract

Hemophilia B Leyden is a unique subtype of hemophilia B, characterized by increasing factor IX activity (FIX:C) after puberty and a lower normal range of FIX:C throughout adulthood. However, to date, no Japanese case has been reported. Here, we report a case of hemophilia B Leyden in a 22-year-old male. He suffered from subgaleal hematoma, and was subsequently diagnosed with hemophilia B (FIX:C 0.2%) in the neonatal period. Both his parents are Japanese. There was no history of hemophilia in his family. FIX:C gradually increased with age (8% at age = 1; 14% at age = 7; 19% at age = 12; 32% at age = 18). FIX:C is within the range 30–40% in recent several years. He once required administration of FIX concentrate against traumatic tongue bleeding at 7 years of age. Genotyping analysis of FIX was performed after informed consent at 21 years of age, and a point mutation (c.–35G>A) was detected. This mutation has been reported previously as the Leyden mutation. Although it has been reported that hemophilia B Leyden is seen in 1.9% of patients with hemophilia B, the present case is the first report of hemophilia B Leyden from Japan.
Literature
1.
go back to reference Funnell AP, Wilson MD, Ballester B, Mak KS, Burdach J, Magan N, et al. A CpG mutational hotspot in a ONECUT binding site accounts for the prevalent variant of hemophilia B Leyden. Am J Hum Genet. 2013;92:460–7.CrossRefPubMedPubMedCentral Funnell AP, Wilson MD, Ballester B, Mak KS, Burdach J, Magan N, et al. A CpG mutational hotspot in a ONECUT binding site accounts for the prevalent variant of hemophilia B Leyden. Am J Hum Genet. 2013;92:460–7.CrossRefPubMedPubMedCentral
2.
go back to reference Radic CP, Rossetti LC, Abelleyro MM, Candela M, Perez Bianco R, de Tezanos Pinto M, et al. Assessment of the F9 genotype-specific FIX inhibitor risks and characterisation of 10 novel severe F9 defects in the first molecular series of Argentinian patients with haemophilia B. Thromb Haemost. 2013;109:24–33.CrossRefPubMed Radic CP, Rossetti LC, Abelleyro MM, Candela M, Perez Bianco R, de Tezanos Pinto M, et al. Assessment of the F9 genotype-specific FIX inhibitor risks and characterisation of 10 novel severe F9 defects in the first molecular series of Argentinian patients with haemophilia B. Thromb Haemost. 2013;109:24–33.CrossRefPubMed
3.
go back to reference Rallapalli PM, Kemball-Cook G, Tuddenham EG, Gomez K, Perkins SJ. An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B. J Thromb Haemost. 2013;11:1329–40.CrossRefPubMed Rallapalli PM, Kemball-Cook G, Tuddenham EG, Gomez K, Perkins SJ. An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B. J Thromb Haemost. 2013;11:1329–40.CrossRefPubMed
4.
go back to reference Japan Foundation for AIDS Prevention. Project entrusted by Ministry of Health, Labour and Welfare. Nationwide Survey on Coagulation Disorders 2015. Published by Japan Foundation for AIDS Prevention, Tokyo. Japan Foundation for AIDS Prevention. Project entrusted by Ministry of Health, Labour and Welfare. Nationwide Survey on Coagulation Disorders 2015. Published by Japan Foundation for AIDS Prevention, Tokyo.
5.
go back to reference Veltkamp JJ, Meilof J, Remmelts HG, van der Vlerk D, Loeliger EA. Another genetic variant of haemophilia B: haemophilia B Leyden. Scand J Haematol. 1970;7:82–90.CrossRefPubMed Veltkamp JJ, Meilof J, Remmelts HG, van der Vlerk D, Loeliger EA. Another genetic variant of haemophilia B: haemophilia B Leyden. Scand J Haematol. 1970;7:82–90.CrossRefPubMed
7.
go back to reference Funnell AP, Crossley M. Hemophilia B Leyden and once mysterious cis-regulatory mutations. Trends Genet. 2014;30:18–23.CrossRefPubMed Funnell AP, Crossley M. Hemophilia B Leyden and once mysterious cis-regulatory mutations. Trends Genet. 2014;30:18–23.CrossRefPubMed
8.
go back to reference Crossley M, Ludwig M, Stowell KM, De Vos P, Olek K, Brownlee GG. Recovery from hemophilia B Leyden: an androgen-responsive element in the factor IX promoter. Science. 1992;257:377–9.CrossRefPubMed Crossley M, Ludwig M, Stowell KM, De Vos P, Olek K, Brownlee GG. Recovery from hemophilia B Leyden: an androgen-responsive element in the factor IX promoter. Science. 1992;257:377–9.CrossRefPubMed
9.
go back to reference Heit JA, Ketterling RP, Zapata RE, Ordonez SM, Kasper CK, Sommer SS. Haemophilia B Brandenberg-type promoter mutation. Haemophilia. 1999;5:73–5.CrossRefPubMed Heit JA, Ketterling RP, Zapata RE, Ordonez SM, Kasper CK, Sommer SS. Haemophilia B Brandenberg-type promoter mutation. Haemophilia. 1999;5:73–5.CrossRefPubMed
10.
go back to reference Kurachi S, Huo JS, Ameri A, Zhang K, Yoshizawa AC, Kurachi K. An age-related homeostasis mechanism is essential for spontaneous amelioration of hemophilia B Leyden. Proc Natl Acad Sci USA. 2009;106:7921–6.CrossRefPubMedPubMedCentral Kurachi S, Huo JS, Ameri A, Zhang K, Yoshizawa AC, Kurachi K. An age-related homeostasis mechanism is essential for spontaneous amelioration of hemophilia B Leyden. Proc Natl Acad Sci USA. 2009;106:7921–6.CrossRefPubMedPubMedCentral
11.
go back to reference Ojha J, Secreto C, Rabe K, Ayres-Silva J, Tschumper R, Dyke DV, et al. Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression. Leukemia. 2014;28:2395–8.CrossRefPubMedPubMedCentral Ojha J, Secreto C, Rabe K, Ayres-Silva J, Tschumper R, Dyke DV, et al. Monoclonal B-cell lymphocytosis is characterized by mutations in CLL putative driver genes and clonal heterogeneity many years before disease progression. Leukemia. 2014;28:2395–8.CrossRefPubMedPubMedCentral
Metadata
Title
First case report of hemophilia B Leyden in Japan
Authors
Atsuki Yamashita
Chiai Nagae
Mika Mori
Tomoko Ashikaga
Tetsuhito Kojima
Masashi Taki
Publication date
01-07-2017
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 1/2017
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-017-2194-4

Other articles of this Issue 1/2017

International Journal of Hematology 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine